Earkart Ltd

🚀 Earkart Ltd’s Growth Blueprint: 510 Clinics by 2027 & Global Expansion

- Targets expanding Shop-in-Shop (SIS) clinics from 49 to 510 by 2027.

- Plans market entry into the US and Australia.

- Expected revenue recovery in H2FY26 due to deferred government orders.

- Operates a 4,500 sq. ft. manufacturing facility in Noida with in-house R&D.

- Certifications: ISO 13485, BIS, and CDSCO approval.

- Business model: SIS clinics (49), government contracts (69% of FY25 revenue), private distribution (29%).

- Global hearing aid market projected to grow at 6.6% CAGR to $12.67B by 2030.

- Secured patent for 'Smart Sound Treatment and Diagnosis System'.

- Showcased OMNI at earAsT, the world’s largest ENT conference.

- FY25 Total Revenue: ₹4,319.21 Lakhs; EBITDA: ₹976.27 Lakhs; PAT: ₹688.17 Lakhs; ROE: 34.55%.

- H1FY26 Revenue: ₹2,228.57 Lakhs (down 5.37% YoY).

- Balance Sheet: Share Capital (₹1,375.39L), Reserves (₹5,230.75L), Total Assets (₹7,818.20L).

- Recognized in Forbes DGEMS 2025 Top 200 High-Impact Companies.

- Product portfolio includes BTE/RIC hearing aids and rehabilitative kits.

- OMNI Audiometer enables remote diagnostics for underserved areas.